Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SI
SI logo

SI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
18.510
Open
18.350
VWAP
18.00
Vol
38.06K
Mkt Cap
368.52M
Low
17.720
Amount
685.08K
EV/EBITDA(TTM)
--
Total Shares
20.74M
EV
291.12M
EV/OCF(TTM)
--
P/S(TTM)
6.47
Shoulder Innovations, Inc. is a commercial-stage medical technology company focused on transforming the shoulder surgical care market. The Company offers advanced implant systems for shoulder arthroplasty. These systems are a core element of its ecosystem, designed to improve the core components of shoulder surgical care, preoperative planning, implant design and procedural efficiency, to benefit each stakeholder in the care chain. Its ecosystem is also comprised of enabling technologies, instrument systems, specialized support and surgeon-to-surgeon collaboration. Its advanced implants are comprised of its aTSA and rTSA systems, which are designed to address the needs of patients and surgeons, and include various, specifically designed components capable of an array of system configurations to facilitate different modes of operation (anatomic or reverse). Its InSet Glenoid technology serves as the foundation for its advanced implant systems and includes a novel InSet design.
Show More

Events Timeline

(ET)
2026-05-13
16:20:00
Shoulder Innovations Q1 Revenue $16.71M Beats Expectations
select
2026-03-10 (ET)
2026-03-10
16:30:00
Shoulder Innovations FY26 Revenue View Growth of 31%-37%
select
2026-03-10
16:30:00
Shoulder Innovations Q4 Revenue $14.4M Beats Expectations
select
2025-12-03 (ET)
2025-12-03
07:10:00
Shoulder Innovations Partners with Interventional Systems for Robotic Surgery Solutions
select

News

NASDAQ.COM
8.5
06-11NASDAQ.COM
Biotech Companies See Significant Stock Gains
  • Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
  • Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
  • Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
  • Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
PRnewswire
1.0
05-26PRnewswire
Shoulder Innovations to Attend Goldman Sachs Healthcare Conference
  • Management Participation: Shoulder Innovations' management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, in Miami Beach, aiming to showcase its innovative technologies and strategies in the shoulder surgical care market.
  • Focus on Shoulder Surgery: The company is dedicated to transforming the shoulder surgical care market by offering advanced implant systems for shoulder arthroplasty, which aim to enhance preoperative planning, implant design, and procedural efficiency, thereby improving patient surgical experiences.
  • Ecosystem Development: Shoulder Innovations' ecosystem includes efficient instrument systems, specialized support, and surgeon-to-surgeon collaboration, designed to address long-standing clinical and operational challenges in the shoulder surgical care market, delivering predictable outcomes and procedural simplicity.
  • Market Impact Potential: By integrating various technologies and support systems, Shoulder Innovations aims to enhance surgical efficiency while increasing stakeholder satisfaction, positioning itself favorably in the competitive medical technology market.
seekingalpha
9.5
05-14seekingalpha
Shoulder Innovations Reports Strong Q1 2026 Earnings with Raised Guidance
  • Significant Revenue Growth: Shoulder Innovations reported Q1 2026 net revenue of $16.7 million, reflecting a 65% year-over-year increase and a 16% sequential rise, indicating strong market performance and sustained growth potential.
  • Margin Improvement: The gross margin for Q1 stood at 77.7%, up from 76.9% in the prior year, primarily driven by improved average selling prices and cost reduction programs, thereby enhancing the company's profitability.
  • Product Launch Progress: The company advanced the InSet 135RFX Humeral Stem from limited user release to full commercial launch and initiated a limited user release of the N22 Glenosphere, demonstrating proactive efforts in new product development and market penetration.
  • Raised Full-Year Guidance: Management raised the full-year 2026 net revenue guidance to a range of $65 million to $68 million from the previous $62 million to $65 million, reflecting confidence in future performance and strong market demand.
seekingalpha
9.5
05-13seekingalpha
Shoulder Innovations Q1 Earnings Beat Expectations
  • Earnings Report: Shoulder Innovations, Inc. reported a Q1 GAAP EPS of -$0.41, aligning with market expectations, indicating stability in the company's recovery towards profitability.
  • Revenue Growth: The company achieved Q1 revenue of $16.71 million, exceeding analyst expectations by $2.18 million, reflecting strong demand for its products and an increase in market share.
  • Market Reaction: Although the EPS remains negative, the revenue beat may boost investor confidence, potentially leading to a positive impact on the stock price.
  • Future Outlook: With revenue growth, Shoulder Innovations is positioned to improve profitability in the coming quarters, further solidifying its market position in the medical device industry.
PRnewswire
5.0
04-27PRnewswire
Shoulder Innovations Launches New Product Line
  • Full Product Launch: Shoulder Innovations announces the full commercial launch of the InSet™ I-135RFX following a successful limited market release and FDA 510(k) clearance for expanded fracture indications, marking a significant advancement in shoulder arthroplasty procedures.
  • Strong Innovation Engine: As the third addition to the InSet humeral stem system in three years, the InSet™ I-135RFX reflects the company's ongoing commitment to innovation aimed at improving patient outcomes even in challenging clinical scenarios.
  • Simplified Surgical Technique: The product has been widely utilized in both anatomic and reverse shoulder arthroplasty, with surgeons particularly valuing its ease of use and seamless integration with the company's two-tray surgical instrumentation system, enhancing surgical efficiency.
  • Clear Market Positioning: Shoulder Innovations aims to address clinical and operational challenges in shoulder surgical care through advanced implant systems and efficient surgical support, driving predictable outcomes and procedural simplicity across the care continuum.
Newsfilter
5.0
04-27Newsfilter
Shoulder Innovations Launches New Product Line
  • Full Product Launch: Shoulder Innovations announces the full commercial launch of the InSet™ I-135RFX following a successful limited market release and FDA 510(k) clearance for expanded fracture indications, marking a significant expansion in the shoulder arthroplasty market.
  • Innovation Milestone: The InSet™ I-135RFX is the third product launched in three years, showcasing the company's innovation capabilities aimed at improving patient outcomes in complex clinical scenarios, thereby enhancing its competitive position in the medical technology sector.
  • Surgical Convenience: The product has been utilized by surgeons in both anatomic and reverse shoulder arthroplasty, praised for its ease of use and seamless integration with the two-tray surgical instrumentation system, which is expected to enhance surgical efficiency and patient satisfaction.
  • Ecosystem Integration: Shoulder Innovations' product line includes advanced implant systems and addresses core elements such as preoperative planning, implant design, and procedural efficiency, aiming to solve long-standing challenges in the shoulder surgical care market by delivering predictable outcomes and procedural simplicity.
Wall Street analysts forecast SI stock price to rise
3 Analyst Rating
Wall Street analysts forecast SI stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
20.00
Averages
22.00
High
23.00
Current: 0.000
sliders
Low
20.00
Averages
22.00
High
23.00
Piper Sandler
Matt O'Brien
maintain
$18 -> $19
AI Analysis
2026-05-08
Reason
Piper Sandler
Matt O'Brien
Price Target
$18 -> $19
AI Analysis
2026-05-08
maintain
Reason
Piper Sandler analyst Matt O'Brien raised the firm's price target on Shoulder Innovations to $19 from $18 and keeps an Overweight rating on the shares. Over the next year, Shoulder Innovations should be launching three new products that would expand its addressable market by $200M-plus, the firm notes. Once these products hit the market, the company will have a comprehensive portfolio to address nearly all of surgeons' needs. Piper expects these product launches to drive higher utilization among the existing core/contender surgeon base, amounting to 180 bps-260 bps of potential revenue upside versus its model in 2026-2028.
BTIG
Buy
maintain
$23 -> $24
2026-03-11
Reason
BTIG
Price Target
$23 -> $24
2026-03-11
maintain
Buy
Reason
BTIG raised the firm's price target on Shoulder Innovations to $24 from $23 and keeps a Buy rating on the shares. The firm continues to view 2026 as a year of accelerating new customer acquisitions, with clear greenfield geographic expansion opportunities in key markets, as well as deepening ASC - Ambulatory Surgery Center - penetration and expanding new products, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SI
Unlock Now

Valuation Metrics

The current forward P/E ratio for Shoulder Innovations Inc (SI.N) is 0.00, compared to its 5-year average forward P/E of -9.14. For a more detailed relative valuation and DCF analysis to assess Shoulder Innovations Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.14
Current PE
0.00
Overvalued PE
-7.51
Undervalued PE
-10.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-12.14
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-8.35
Undervalued EV/EBITDA
-15.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.68
Current PS
4.46
Overvalued PS
5.81
Undervalued PS
3.56

Financials

AI Analysis
Annual
Quarterly

Whales Holding SI

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Shoulder Innovations Inc (SI) stock price today?

The current price of SI is 17.77 USD — it has decreased -4.2

What is Shoulder Innovations Inc (SI)'s business?

Shoulder Innovations, Inc. is a commercial-stage medical technology company focused on transforming the shoulder surgical care market. The Company offers advanced implant systems for shoulder arthroplasty. These systems are a core element of its ecosystem, designed to improve the core components of shoulder surgical care, preoperative planning, implant design and procedural efficiency, to benefit each stakeholder in the care chain. Its ecosystem is also comprised of enabling technologies, instrument systems, specialized support and surgeon-to-surgeon collaboration. Its advanced implants are comprised of its aTSA and rTSA systems, which are designed to address the needs of patients and surgeons, and include various, specifically designed components capable of an array of system configurations to facilitate different modes of operation (anatomic or reverse). Its InSet Glenoid technology serves as the foundation for its advanced implant systems and includes a novel InSet design.

What is the price predicton of SI Stock?

Wall Street analysts forecast SI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SI is22.00 USD with a low forecast of 20.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Shoulder Innovations Inc (SI)'s revenue for the last quarter?

Shoulder Innovations Inc revenue for the last quarter amounts to 16.71M USD, increased 64.90

What is Shoulder Innovations Inc (SI)'s earnings per share (EPS) for the last quarter?

Shoulder Innovations Inc. EPS for the last quarter amounts to -0.41 USD, increased 78.26

How many employees does Shoulder Innovations Inc (SI). have?

Shoulder Innovations Inc (SI) has 72 emplpoyees as of June 24 2026.

What is Shoulder Innovations Inc (SI) market cap?

Today SI has the market capitalization of 368.52M USD.